SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE TO
Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934
(Amendment No. 4)

DEPOMED, INC.
(Name of Subject Company (Issuer))

Diosail Merger Corporation
(Name of Offeror)
A Wholly-Owned Subsidiary of

Horizon Pharma Public Limited Company
(Name of Offerors)
(Names of Filing Persons (identifying status as offeror, issuer or other person))

Common Stock, no par value
(Title of Class of Securities)

249908104
(CUSIP Number of Class of Securities)

Timothy P. Walbert
Horizon Pharma plc
Connaught House, 1st Floor
1 Burlington Road, Dublin 4, Ireland
011 353 1 772 2100

(Name, address and telephone number of person authorized to receive notices and communications on behalf of the filing person)

Barbara Borden
Kay Chandler
Sean Clayton
Cooley LLP
4401 Eastgate Mall
San Diego, California 92121
Telephone: (858) 550-6000

Rodd M. Schreiber
Richard J. Grossman
Meagher & Flom LLP
155 N. Wacker Drive
Chicago, Illinois 60606
Telephone: (312) 407-0700

CALCULATION OF FILING FEE

<table>
<thead>
<tr>
<th>Transaction Valuation(1)</th>
<th>Amount of Filing Fee(2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2,233,908,319.56</td>
<td>$259,580.15</td>
</tr>
</tbody>
</table>
Pursuant to Rule 0-11 under the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act, and solely for the purpose of calculating the filing fee, the market value of the securities to be received was calculated as the product of (1) 84,521,692 shares of common stock, no par value, of Depomed, Inc., which we refer to as Depomed, and which common stock we refer to as Depomed common stock (being the sum of (i) 60,311,961 shares of Depomed common stock outstanding as of July 30, 2015 (as reported in Depomed’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2015), (ii) 6,748,006 shares of Depomed common stock issuable upon the exercise of outstanding stock options as of December 31, 2014 (as reported in Depomed’s Annual Report on Form 10-K for the year ended December 31, 2014), (iii) 544,464 shares of Depomed common stock subject to restricted stock awards as of December 31, 2014 (as reported in Depomed’s Annual Report on Form 10-K for the year ended December 31, 2014), and (iv) 19,167,261 shares of Depomed common stock issuable upon the conversion of Depomed’s outstanding convertible notes assuming that all such notes are converted after the completion of the offer on the expiration date but prior to the consummation of the second-step merger, and that Depomed elects to settle such notes using only shares of Depomed common stock (and for purposes of such settlement such shares are valued at $33.00 per share), less 2,250,000 shares of Depomed common stock in which Horizon Pharma, Inc. has an ownership interest, which will not be tendered in the offer and will be cancelled in any merger with Depomed) and (2) the average of the high and low sale prices of Depomed common stock as reported on the NASDAQ Global Select Market on September 4, 2015 ($26.43).

Computed in accordance with Rule 0-11 under the Exchange Act to be $259,580.15, which is equal to 0.0001162 multiplied by the proposed maximum aggregate offering price of $2,233,908,319.56.

Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

☐ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

☒ third-party tender offer subject to Rule 14d-1.
☐ issuer tender offer subject to Rule 13e-4.
☐ going-private transaction subject to Rule 13e-3.
☐ amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐
This Amendment No. 4 to the Tender Offer Statement on Schedule TO amends and supplements the Tender Offer Statement on Schedule TO originally filed with the Securities Exchange Commission on September 8, 2015 (as amended and together with any subsequent amendments and supplements thereto, the “Schedule TO”) by Horizon Pharma Public Limited Company, a public limited company formed under the laws of Ireland (“Horizon”), and Diosail Merger Corporation, a California corporation and a wholly owned subsidiary of Horizon (“Purchaser”). The Schedule TO relates to the offer by Horizon, through Purchaser, to exchange each issued and outstanding share of common stock, no par value (including the associated rights to purchase preferred stock, the “Depomed common stock”), of Depomed, Inc., a California corporation (“Depomed”), that is validly tendered and not properly withdrawn prior to the expiration date, for 0.95 ordinary shares of Horizon, nominal value $0.0001 per share (including any cash paid in lieu of a fractional Horizon ordinary share), subject to the procedures described in (1) the Offer to Exchange, dated September 25, 2015 (the “Offer to Exchange”), and (2) the related Letter of Transmittal (the offer reflected by such terms and conditions, as they may be amended, supplemented or extended from time to time, constitutes the “Offer”).

All capitalized terms used in this Amendment No. 4 and not otherwise defined have the respective meanings ascribed to them in the Schedule TO.

**Item 12. Exhibits.**

*Item 12 of the Schedule TO is hereby amended and supplemented as follows:*

<table>
<thead>
<tr>
<th>EXHIBIT NO.</th>
<th>DOCUMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a)(5)(D)</td>
<td>Amended slide in investor presentation first used by Horizon Pharma Public Limited Company on October 13, 2015.</td>
</tr>
</tbody>
</table>
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Diosail Merger Corporation

By: /s/ Timothy P. Walbert
Name: Timothy P. Walbert
Title: Chairman, President and Chief Executive Officer

Horizon Pharma plc

By: /s/ Timothy P. Walbert
Name: Timothy P. Walbert
Title: Chairman, President and Chief Executive Officer

Date: October 13, 2015
## EXHIBIT INDEX

<table>
<thead>
<tr>
<th>EXHIBIT NO.</th>
<th>DOCUMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>(a)(1)(A)</td>
<td>Form of Letter of Transmittal.*</td>
</tr>
<tr>
<td>(a)(1)(B)</td>
<td>Form of Notice of Guaranteed Delivery.*</td>
</tr>
<tr>
<td>(a)(1)(C)</td>
<td>Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.*</td>
</tr>
<tr>
<td>(a)(1)(D)</td>
<td>Form of Letter to Clients for use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.*</td>
</tr>
<tr>
<td>(a)(4)(A)</td>
<td>Offer to Exchange, dated September 25, 2015.**</td>
</tr>
<tr>
<td>(a)(5)(A)</td>
<td>Press Release, dated September 8, 2015.***</td>
</tr>
<tr>
<td>(a)(5)(B)</td>
<td>Letter to Depomed, Inc. Shareholders, dated September 10, 2015.***</td>
</tr>
<tr>
<td>(a)(5)(C)</td>
<td>Investor presentation first used by Horizon Pharma Public Limited Company on September 17, 2015, as amended.***</td>
</tr>
<tr>
<td>(a)(5)(D)</td>
<td>Amended slide in investor presentation first used by Horizon Pharma Public Limited Company on October 13, 2015.</td>
</tr>
<tr>
<td>(b)</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>(d)</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>(g)</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>(b)</td>
<td>Opinion of Cooley LLP regarding certain tax matters.****</td>
</tr>
</tbody>
</table>

* Incorporated by reference to the Horizon Registration Statement on Form S-4 filed on September 8, 2015.
** Incorporated by reference to Amendment No. 1 to the Horizon Registration Statement on Form S-4 filed on September 25, 2015.
*** Previously filed.
**** To be filed by amendment.
Published Analyst Reports and Investors That We Have Spoken With Are Overwhelmingly Supportive

“Viewing the proposed Depomed transaction within that broader context of Horizon’s evolution, we believe this transaction makes exceedingly good strategic sense, is nicely value creating and provides enhanced and durable diversification.”

Ken Cacciato
Cowen and Company, 7/21/2015

“Per our earlier note, we believe the asset is worth more in the hands of Horizon given the greater S&M resources Horizon could provide, cost savings opportunity, ability to refinance the 10.75% debt and expected reduction of the tax burden.”

Randall Stanicky
RBC, 7/21/2015

“The perception that this deal may not generate an adequate amount of synergies to be attractive does not make sense to us. If we looked through Horizon’s past deal transaction history, none was built on cost cutting - rather all were based on generating revenue upside from increased promotion and better pharmacy pull through. We see the Depomed deal as being no different.”

Difei Yang
Brean Capital, 7/8/2015

“The debate whether Depomed overpaid for Nucynta is yet to be determined, but we believe this is a growth product and the numbers work better within Horizon with the significant tax advantages.”

Marc Goodman
UBS, 7/7/2015

“We continue to view a HZNP-DEPO combination as attractive, and believe HZNP has made a strong case to DEPO shareholders.”

Annabel Samimy
Stifel, 8/3/2015

“Per our earlier note, we believe the asset is worth more in the hands of Horizon given the greater S&M resources Horizon could provide, cost savings opportunity, ability to refinance the 10.75% debt and expected reduction of the tax burden.”

Randall Stanicky
RBC, 7/21/2015

“The perception that this deal may not generate an adequate amount of synergies to be attractive does not make sense to us. If we looked through Horizon’s past deal transaction history, none was built on cost cutting - rather all were based on generating revenue upside from increased promotion and better pharmacy pull through. We see the Depomed deal as being no different.”

Difei Yang
Brean Capital, 7/8/2015

“As of 6/30/2015, Horizon Shareholders Owned 66% of Depomed’s Outstanding Shares

Source: Wall Street Research.
Note: Permission to use quoted material was neither sought nor obtained.
(1) Factset and NASDAQ.